Finanznachrichten2d
Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Jan. 14, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today ...
Quoin announces clinical data from ongoing Pediatric Netherton Syndrome study
Quoin Pharmaceuticals (QNRX) announces interim clinical data from its ongoing Investigator Pediatric Netherton Syndrome clinical study. The ...
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” ...